Allogeneic Cell Therapy Market 2030: A Surge in Innovation and Investment
Allogeneic Cell Therapy Market Overview The global allogeneic cell therapy market was valued at USD 255.6 million in 2022 and is expected to reach USD 1.72 billion by 2030, growing at a CAGR of 27.4% from 2023 to 2030. This growth is primarily driven by the rising prevalence of chronic conditions such as cancer, cardiovascular diseases, autoimmune disorders, and genetic illnesses, which continue to demand advanced therapeutic interventions. According to the American Cancer Society, approximately 1.9 million new cancer cases were diagnosed in the U.S. in 2022, leading to over 609,000 deaths. Coupled with a globally aging population, this trend highlights an increasing burden of chronic diseases, reinforcing the need for innovative treatments like allogeneic cell therapy to improve patient outcomes. Impact of COVID-19 The COVID-19 pandemic negatively impacted the allogeneic cell therapy market, slowing down research and development activities. It disrupted various operations, includ...